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Differential scanning calorimetryValsartan is a marketed drug with high afﬁnity to the type 1 angiotensin (AT1) receptor. It has been reported
that AT1 antagonists may reach the receptor site by diffusion through the plasma membrane. For this reason
we have applied a combination of differential scanning calorimetry (DSC), Raman spectroscopy and small and
wide angle X-ray scattering (SAXS and WAXS) to investigate the interactions of valsartan with the model
membrane of dipalmitoyl-phosphatidylcholine (DPPC). Hence, the thermal, dynamic and structural effects in
bulk as well as local dynamic properties in the bilayers were studied with different valsartan concentrations
ranging from 0 to 20 mol%. The DSC experimental results showed that valsartan causes a lowering and
broadening of the phase transition. A splitting of the main transition is observed at high drug concentrations.
In addition, valsartan causes an increase in enthalpy change of the main transition, which can be related to the
induction of interdigitation of the lipid bilayers in the gel phase. Raman spectroscopy revealed distinct
interactions between valsartan with the lipid interface localizing it in the polar head group region and in the
upper part of the hydrophobic core. This localization of the drug molecule in the lipid bilayers supports the
interdigitation view. SAXS measurements conﬁrm a monotonous bilayer thinning in the ﬂuid phase,
associated with a steady increase of the root mean square ﬂuctuation of the bilayers as the valsartan
concentration is increased. At high drug concentrations these ﬂuctuations are mainly governed by the
electrostatic repulsion of neighboring membranes. Finally, valsartans' complex thermal and structural effects
on DPPC bilayers are illustrated and discussed on a molecular level.f Organic and Pharmaceutical
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39 040 375 8708; fax: +39 040
oustakos),
l rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
The renin–angiotensin system (RAS) is a bioenzymatic cascade [1]
well known to inﬂuence the aldosterone stimulation and water
homeostasis. When the amount of blood decreases in a human body,
the kidneys start to secrete renin, which in turn stimulates the
production of angiotensin I (Ang I). Ang I is then converted to
angiotensin II (Ang II) by the angiotensin-converting enzyme (ACE).
Finally, Ang II binds at the type 1 angiotensin (AT1) receptor [2], and
causes blood vessels to constrict resulting in an elevated bloodpressure. Thus, the RAS has received great attention in developing
novel synthetic antihypertensive drugs.
Theﬁrst drugdesign strategywas to blockACE and subsequently the
formation of the vasoconstrictive hormone Ang II. Captopril® was the
ﬁrst ACE inhibitor developed [3] and was considered a major
breakthrough, because of its novel mechanism of action. However,
ACE inhibitors have undesired side effects such as dry mouth and
angioedema, which precluded them from being the ideal drugs for
hypertension. Secondly, it is well known that also other non-ACE
enzymatic pathways for the formation of Ang II exist [4], so that the
inhibition of the RAS by ACE inhibitors is incomplete. A similar strategy
is followed in the rational drug design of renin inhibitors. Only recently,
the synthetic molecule aliskiren, which blocks the renin activity, has
entered the market with the trade name Tekturna® (Novartis) [5].
The second strategy to reduce RAS activity focuses on a class of
synthetic molecules that block the AT1 receptor, i.e., they function as
Ang II antagonists. Synthetic peptide analogs and other non-peptide
Ang II antagonists are designed to mimic the C-terminal segment of
Ang II [6]. In this class of antihypertension drugs losartan was the ﬁrst
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angiotensin receptor blockers (ARBs) have been especially developed
to produce a more effective inhibition of the action of Ang II as
compared to other drug classes as well as to decrease the side effects
[8–16].
Valsartan (Diovan®) is the second orally active non-peptide Ang II
antagonist marketed in Europe and the USA for the treatment of
hypertension. Its effectiveness is at least equivalent to ACE inhibitors,
diuretics, β-blockers and calcium antagonists, and it has the
advantage of not causing cough and lower limb edema such as ACE
inhibitors do [17–19]. Valsartan differs structurally from losartan by
an alkylated aminoacid that replaces the heterocyclic moiety of the
compound. Like losartan, its rational design is based on themimicry of
the C-terminal segment of Ang II (Fig. 1, red circle) [20,21].
Recently, we have reported that losartan and subsequently also
other ARBs may exert their mode of action through a two-step
mechanism, which involves membrane incorporation and lateral
diffusion towards the receptor site, rather than a direct drug–receptor
interaction [22,23]. A two-step mechanism has been also suggested
for other amphiphilic molecules such as cannabinoids and calcium
channel antagonists [24–26].
In order to profoundly examine the role of the lipid bilayers, the
interaction of valsartan with a simple model membrane system was
studied. Usually, phosphatidylcholine (PC)–water or PC–cholesterol–
water systems are applied to mimic plasma cell membranes. In this
work,multilamellar vesicles (MLVs) of dipalmitoyl-phosphatidylcholine
(DPPC) formed in excess of water were used to model the plasma
membranes of the vasculature. Note that AT1 receptors are found in
many tissues [1], but primarily in the plasma membranes of the blood
vessel system, where ARB's attachment to the receptors causes a
decrease in vasoconstriction [27]. Further, note that saturatedPCs are the
most abundant lipid species in the plasmamembrane of the vasculature
with a share 40–65% [28,29]. Conveniently, the thermodynamic and
structural properties of DPPC have been extensively studied [30–35].
The main focus of this study are valsartan–lipid interactions
observed in a temperature range from 20 up to 50 °C, i.e., in the gel
and ﬂuid phases of DPPC bilayers. Both, the pre- and main transitions
have been characterized by Differential Scanning Calorimetry (DSC),
Raman spectroscopy, small and wide angle X-ray scattering (SAXS
and WAXS), and dilatometry experiments (only at 50 °C). These
methodologies provide insight into the thermodynamic changes in
the membrane in the presence of valsartan, allow the determination
of chain ﬂuidity and mobility alterations, and ﬁnally permit to
correlate the spectroscopic results with the structural modiﬁcations
on a molecular level. Moreover, the swelling behavior of the MLVs
helps to understand the role of charged valsartan molecules. A
realistic bilayer model for partial interdigitation is presented, and the
complex thermal valsartan–lipid behavior is discussed.N
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Fig. 1. Chemical structures of valsartan and losartan. The molecular part mimicking the
C-terminal segment of angiotensin II is circled in red.2. Materials and methods
2.1. Sample preparation
Lα-dipalmitoyl-phosphatidylcholine (Lα-DPPC, 99+%) was pur-
chased from Avanti Polar Lipids Inc (Alabaster, AL) and spectroscopic
grade CHCl3 from Sigma Aldrich (St. Louis, MO). Valsartan was
generously donated by Novartis. For DSC and Raman measurements,
appropriate amounts of DPPC and valsartan diluted in chloroform
were mixed, dried under a stream of N2 and then stored under
vacuumovernight. After dispersing inwater (50%w/w), ca. 5 mgwere
sealed in stainless steel capsules obtained from Perkin-Elmer (Nor-
walk, CT) and used for differential scanning calorimetry, and 40 mg
were positioned in the sample holder for Raman spectroscopy
measurements. For X-ray scattering experimentsMLVswere prepared
according to the above protocol with ﬁnal lipid weight concentrations
of 5% and 20%. The drug concentrations used for the different
experiments were x=0.01 (1 mol% valsartan), x=0.02, x=0.05,
x=0.10 and x=0.20 .
2.2. Differential scanning calorimetry
Thermal scans were carried out using a Perkin-Elmer DSC-7
calorimeter (Norwalk, CT). All samples were scanned from 10 to 60 °C
until identical thermograms were obtained using a scanning rate of
2.5 °C/min. The temperature scale of the calorimeter was calibrated
using indium (Tm=156.6 °C) and DPPC bilayers (Tm=41.2 °C). The
following diagnostic parameters were used for the study of drug to
membrane interactions: Tm (maximum of the recorded heat capacity),
Tonset (the starting temperature of the phase transition) and ΔT (the
full width at half-height of the phase transition), and the respective
parameters concerning the pretransition. An empty pan for the base
line and a sample containing double-distilled water were run for the
temperature range of 10–60 °C as a reference for the background. This
background was subtracted from each thermal scan of the samples.
The area under the peak represents the enthalpy change during the
transition (ΔΗ). The mean values of ΔΗ of three identical scans were
tabulated.
2.3. Raman spectroscopy
The Raman spectra were obtained from 3500 to 400 cm−1 with
4 cm−1 spectral resolution using a Perkin-Elmer NIR FT-spectrometer
(Spectrum GX II, Norwalk, CT) equipped with CCD detector (Norwalk,
CT). The measurements were performed at a temperature range of
27–50 °C. The laser power (near IR-Nd:YAG laser with a wavelength
of 1064 nm, Norwalk, CT) was controlled to be constant within
400 mW during the experiments. 1500 scans were accumulated and
back scattering light was collected.
2.4. Small and wide angle X-ray scattering
Simultaneous small and wide-angle X-ray scattering (SAXS and
WAXS=SWAXS) experiments were carried out at the Austrian SAXS
beamline (Elettra Laboratory, Sincrotrone Trieste, Italy) [36]. Two
linear one-dimensional gas detectors were used covering the q ranges
(q=4π sinθ/λ; where 2θ is the scattering angle and λ=1.54 Å the
selected X-ray wavelength) between 0.01 and 0.6 Å−1 for SAXS and
from 0.67 to 1.95 Å−1 for WAXS, respectively. The angular depen-
dence of the scattered intensity was calibrated with silver behenate
(d=58.38 Å) for the SAXS regime, and with para-bromo benzoic acid
for the WAXS regime. The instrumental resolution was determined to
have a full width at half maximum of Δq=2.23 10−3 Å−1. The lipid
dispersions were measured in quartz glass capillaries (diameter
1 mm) and thermostated in a custom-built sample holder block of
brass, which was connected to a circulating water bath (Unistat CC,
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Fig. 2. DSC scans of DPPC bilayers containing valsartan at molar ratios x=0.00, 0.01, 0.05
and 0.20. The thermal scan attributed to DPPC bilayers shows two distinct thermal events.
The incorporation of the drug eliminates the small endothermic event (pretransition) for
xN0.01. The higher the incorporated concentration of the drug, the broader the transition
width and the lower the phase transition temperature. At 5 and 20 mol% valsartan
incorporation, the main transition splits into components (cp. Table 1).
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equilibrated before exposure for a period of 10 min. Exposure times
were 2–3 min. Background corrected SAXS patterns were analyzed in
the full q-range allowing the application of the paracrystalline ansatz
for lattice disorder (used for the gel-phase ﬁtting) as well as of the
modiﬁed Caillé theory (used for the ﬂuid phase ﬁtting). The technique
and underlying premises have been described previously in detail
[37,38] and for reviews, see ref. [34,39]. The bilayermodel used and its
applications have been recently presented [40]. From the ﬁts to the
scattered intensities I=S(q)|F(q)|2/q2 (S(q): structure factor; F(q):
form factor) we directly obtained the lamellar repeat distance d and
the head group-to-head group thickness dHH. The width σH of the
Gaussian peak applied to model electron density proﬁle of the head
group region was ﬁxed to 3 Å. Note that steric bilayer thicknesses are
not explicitly discussed in this work, but can easily be obtained by e.g.
applying the equation dB=dHH+4σH [38]. In the gel phase, the
ﬂuctuations of lamellar stacking disorder σ(gel) were determined
from the paracrystalline structure factor. Fluctuations of the intersti-
tial water layer of ﬂuid bilayers were derived via the bending
ﬂuctuation or Caillé parameter,
η=
π kBT
2d2
ﬃﬃﬃﬃﬃﬃﬃﬃ
KCB
p ð1Þ
directly from the ﬁts. η depends onmembrane bending rigidity KC and
the bulk modulus of interactions B. The mean square ﬂuctuation in
the water spacing between the bilayers was then obtained from
σ(ﬂuid)2=η d2/π2 (for a review on bending ﬂuctuations see [34]).
The lateral area per molecule in the ﬂuid phase was determined
from
A xð Þ = 2⋅V xð Þ
dLuzzati xð Þ
≈2⋅V xð Þ
dHH xð Þ
; ð2Þ
where V is the effective molecular volume (cf. to section 2.4) and
dLuzzati is the membrane thickness that is deﬁned by the Gibbs
dividing surface [41]. Note that for pure DPPC bilayers in the ﬂuid
phase dLuzzati has nearly the same value as dHH [42]. The inﬂuence of
insertion of valsartan into the bilayers onto the Gibbs dividing surface
was not considered. In the case of a linear dependence of A(x) one can
extract estimates for the partial molecular areas ADPPC and Aval by the
relation [43]:
A xð Þ = x Aval + 1−xð Þ⋅ADPPC: ð3Þ
2.4. Dilatometry
The density ρ of the liposomal dispersions has been determined
using a DSA 5000 density analyzer (Anton Paar, Graz, Austria). Further
experimental details are described in [44]. From the density data the
apparent speciﬁc partial lipid volumes were calculated using the
relation
φV = 1 = ρo⋅ 1− ρ−ρoð Þ= c½ ; ð4Þ
where ρ is the measured density of the solution, ρo is the density of
the solvent (0.988 g/cm3) and c is the solute concentration (5 mg/
cm3). The effective molecular volume V of the valsartan/DPPC
mixtures were derived according to Greenwood et al. [45] by
V xð Þ = x⋅Mval + 1−xð Þ⋅MDPPC
NA
⋅φV ð5Þ
where Mval=436 and MDPPC=734 g/mol are the molecular weights
of valsartan and DPPC, respectively, NA is the Avogadro's number, and
x is the valsartan fraction. Assuming that valsartan does not affect themolecular volume of DPPC, i.e., condense or expand, V can be
estimated from
V xð Þ = x Vval + 1−xð Þ⋅VDPPC ð6Þ
using Vval=597 Å3 (estimated from valsartan's density in the solid
state ρ=1.20±0.02 g/cm3 [46] and its molecular weight) and value
of VDPPC=1228 Å3 [45].
3. Results
3.1. Differential scanning calorimetry
The recorded calorimetric scans from DPPC multilamellar vesicles
in excess of water are presented in Fig. 2 for valsartan fractions of
x=0, 0.01, 0.05 and 0.20. For the x=0 and 1 mol% samples two
characteristic endothermic peaks are observed corresponding to the
pre- and the main transition, respectively. Below pretransition
temperature, Tpre , the lamellar gel phase, Lβ′, is present, in which
the lipid chains are in all-trans conformation [47], and as depicted
schematically in Fig. 2 are tilted with respect to membrane normal
about 32° [48]. Above the main transition temperature, Tm, the ﬂuid
lamellar phase, Lα, is apparent. An intermediate phase, Pβ′, is observed
in the temperature range from Tpre to Tm, in which the bilayers are
modulated by a periodic ripple (ripple phase) [49]. The measured
transition temperatures and enthalpies for the pure DPPC–water
system are in good agreement with literature values [30] (Table 1).
The presence of valsartan modulates the following thermal events. At
only 1 mol% of the drug, the pretransition is almost suppressed, the
enthalpy is lowered by a factor of three and the transitionwidth spans
over 7–8 °C. This clearly illustrates the interface activity of the drug
molecule. Further, with increasing drug concentration, the main
transition temperature and the transition cooperativity decrease
monotonically. This demonstrates that valsartan affects increasingly
the alkyl chain packing, when the concentration is increased. A closer
look at the main transition for 5 and 20 mol% valsartan concentration,
reveals a splitting of the transition into two components (Table 1:
components I and II). The total enthalpy of the main transition
increases quite signiﬁcantly from 7.5 to 9.8 kcal/mol for x=0.01–0.20.
As we will discuss later this enthalpy increase indicates at least a
partial interdigitation of the alkyl chains.
Table 1
Thermodynamic parameters of pure DPPC bilayers and with valsartan (VAL)
incorporated at molar ratios x=0.01, 0.05 and 0.20. The pretransition as well as
main transition parameters Tpre, ΔTpre Tm, ΔTm and ΔΗ are given.
Samples Tpre
(°C)
ΔTpre
(°C)
ΔΗpre
(kcal/mol)
Tm
(°C)
ΔTm
(°C)
ΔΗm (kcal/mol)
DPPC
(x=0.0)
35.2 1.8 1.12±0.02 41.2 1.4 7.35±0.07
DPPC/VAL
(x=0.01)
29.8 4.7 0.38±0.01 40.5 1.3 7.53±0.07
DPPC/VAL
(x=0.05)
– – – I: 37.6 1.8 1.64±0.02+
6.05±0.06=
7.69±0.07
II: 39.2 1.8
DPPC/VAL
(x=0.20)
– – – I: 34.9 1.3 6.25±0.06+
3.54±0.03=
9.80±0.09
II: 36.4 2.0
The table refers to experiments displayed in Fig. 2.
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Fig. 3. I1090/1130 vs. temperature plots for (A) pure DPPC (solid circles), (B) DPPC
bilayers containing x=0.20 of valsartan (open circles), and in superposition (C). DSC
data have been included in ﬁrst two panels by vertical lines: transition temperatures are
identiﬁed with dashed-dotted lines and the complete transition-regime is marked by
dotted lines (cp. Fig. 2).
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Raman spectra of pure DPPC bilayers and in the presence of
x=0.20 valsartan were obtained in a temperature range of 27–50 °C
and were recorded in a range of 400–3500 cm−1. The transition
behavior was especially characterized by the C–C and C–H stretching
modes. In particular the C–H stretching bands at ~2880 cm−1 and
~2850 cm−1 have been analyzed, which are assigned to symmetric
and antisymmetric stretching modes in the methylene groups (CH2),
respectively, while the band at ~2935 cm−1 is correlated to the chain
terminal methyl C-H symmetric stretching modes [50,51]. Further,
spectral bands near 1100 cm−1 related to the C–C stretching modes
[52] have been investigated (for a recent overview on Raman spectra
of DPPC bilayers see ref. [53]).
The bands at ~1090 cm−1 and ~1130 cm−1 reﬂect the C–C
stretching modes in gauche and trans conformation, respectively,
i.e., intramolecular trans-gauche conformational changes within the
hydrocarbon chain region can be monitored directly by the intensity
ratio I1090/1130. This peak height intensity ratio allows the direct
comparison of the bilayers order–disorder transitions between
liposome preparations without or with drug incorporation [54]. In
Fig. 3 the changes in I1090/1130 intensity ratio in pure DPPC as well as
DPPC/valsartan bilayers are presented (x=0 and 0.2). The transition
temperatures compare well to the results found from the calorimetric
measurements (Fig. 3A, B), and it is clearly seen that valsartan induces
a lowering of the gauche/trans ratio across the gel to ﬂuid phase
transition: ΔI drops from 0.83 to about 0.54, which means a reduction
of about 35%. As can be seen in Fig. 3C, valsartan induces in part
already at low temperatures (25–35 °C) some chain disorder in the gel
phase, the main differences, however, are apparent in the ﬂuid phase.
The presence of valsartan reduces gauche to trans isomerizations by
about 15% at 50 °C.
The most intense bands in the Raman spectrum of lipid samples
are given in the methylene C–H stretching mode region 2800–
3100 cm−1, which are commonly used to monitor changes in the
lateral packing properties and mobility of the lipid chain in both gel
and liquid crystalline bilayer systems [55]. In particular, the analysis of
the symmetrical and antisymmetrical methylene stretching bands
allows investigating the thermotropic phase behavior of lipids. Levin
and co-workers were the ﬁrst to introduce the intensity ratio of these
two bands I2850/I2880 as an order parameter [32]. This ratio describes
the main changes occurring in the hydrocarbon chain region of the
lipids. It is sensitive to subtle changes in conformational order from
rotations, kinks, twists and bends of the lipid chains[56]. In Fig. 4A the
order parameter is plotted for pure DPPC bilayers. As given for the
above described I1090/1130 ratio, also the I2850/2880 parameter displays
clearly the three different phase regions of Lβ′, Pβ′ and Lα. Moreover,
the transition temperatures from the DSC results are well in
accordance. Although the change of ΔI in the presence of valsartanis almost the same (Fig. 4B), the absolute values of I2850/I2880 are
clearly smaller in the pure gel and ﬂuid phase regimes. As we will
discuss later, this gives a clear indication for at least partial lipid
interdigitation [57].
Another intensity ratio, namely I2935/2880, measures effects
originating from changes both in interchain and intrachain processes
in the bilayer. Although the C–H stretching mode region consists of
many superimposed vibrational transitions, the peak height intensity
ratio is sensitive to monitor the lipid phase transitions [54,57,58].
However, the overall effect of valsartan on this parameter is not as
remarkable as on the other two ratios discussed above. Nevertheless,
the earlier onset of chain melting can be seen also here (inset of
Fig. 4C).
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Fig. 4. I2850/2880 vs. temperature plots for (A) pure DPPC (solid circle), (B) DPPC bilayers
containing x=0.20 of valsartan (open circles), and in superposition (C). DSC data have
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identiﬁed with dashed-dotted lines and the complete transition-regime is marked by
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ratio.
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evidence for the incorporation of valsartan in the monolayer leaﬂets
of the DPPC membrane (data recorded at 43 °C). First, the band at
714 cm−1 which corresponds to C-N stretch vibrations, shows a shift
to slightly higher wavenumbers, when valsartan is incorporated in
lipid bilayers. Second, shift and line shape changes by valsartan at a
band centered around 1720 cm−1 are observed. This indicates
changes in the stretching vibrations of the C–O bonds, which are
present in the ester groups of DPPC. Both observations prove that
valsartan interacts with the PC head groups. Third, valsartan caused a
shift of the 1296 cm−1 band to 1293 cm−1, which corresponds to
stretching vibrations in the (CH)2 region of the acyl chains. Thus,direct evidence of valsartan interactions also with hydrophobic
moieties of the DPPC bilayers is given.
3.3. X-ray scattering
Similar to the DSC scans, also simultaneous time-resolved SAXS
andWAXSmeasurements were carried out onMLV dispersions. In the
experiment from Fig. 5 the bilayers contained 5 mol% valsartan, and
bilayer stacking as well as lipid chain packing were monitored in a
temperature range from 20 to 50 °C with a temperature resolution of
1 °C per minute. In Fig. 5A the ﬁrst two diffraction orders of the
lamellar gel and ﬂuid phase can be seen. In agreement with DSC
results no signs for a ripple phase formation can be traced [59] (cp.
Fig. 2). However, the lamellar repeat distance in the lamellar gel is
anomalously high, i.e., from 20 to about 40 °C the d-spacing equals
~72 Å. Note that for the pure DPPC bilayer phase, the d-spacing lies
around 64 Å (cp. Table 2). After the chain melting is completed, the Lα
phase forms with a ﬁnal d-value of about 67 Å. Interestingly, the
intensities of the Bragg peaks in the ﬂuid phase are signiﬁcantly
stronger than in the gel-phase, which means that the amount of
spatially uncorrelated membranes is actually higher in the gel-phase
as compared to the Lα phase. In this respect, it is also important to
observe that the quasi long range order already improves signiﬁcantly
after the ﬁrst main transition component at 37 °C is completed
(indicated by the strong intensity increase of the diffraction peaks
several degrees before the Lα phase forms; cp. Fig. 2, Table 1). Thus, a
two-step transition is also reﬂected in the SAXS data. The chain order–
disorder transition is measured by WAXS (Fig. 5B). The strong
reﬂection at q=1.49 Å−1 arises from hexagonally packed chains and
its intensity starts to decrease monotonically in the melting regime
from 37 to 42 °C (Fig. 5C). In the Lα phase only diffuse scattering is
apparent with a broad peak centered at about q~1.4 Å−1. The
corresponding d-values are given in Fig. 5D, and show that in the
gel-phase the nearest chain–chain distance continuously increases
with temperature from 4.21 to 4.27 Å.
In Fig. 6 we take a closer look to the scattering patterns of DPPC
bilayers in the presence of x=0.2 valsartan at 20 and 50 °C,
respectively. Again, we observe that valsartan induces stacking
disorder in the MLVs, and that this disorder is stronger in the gel
phase. In the bottom scattering pattern of Fig. 6A (20 °C), mainly form
factor contributions are present accompanied only by a weak ﬁrst
order diffraction peak at q=0.08 Å−1. Both SAXS patterns have been
analyzed by global ﬁtting procedures [37], and best ﬁts are displayed
by solid red lines. The corresponding electron density proﬁles are
displayed in Fig. 6B, and the most important structural parameters as
well as the membrane ﬂuctuation parameter σ are summarized in
Table 2. Note that for the gel phase σ(gel) is deduced from the
paracrystalline theory for lattice disorder of second type [60], i.e.,
practically ﬂat bilayers are considered to oscillate with respect to the
neighboring membranes, while for the ﬂuid phase σ(ﬂuid) is deduced
from the application of the modiﬁed Caillé theory [61,62]. In the later
theory also bilayer undulations are included. The most obvious
alterations caused by valsartan are the loose stacking in the gel phase
as evidenced by the large interstitial water layer (Δ(d−dHH)=+27 Å
and Δσ=+13 Å; Table 2) and the enhanced diffuse scattering due to
positionally uncorrelated membranes. The lipid chain packing area AC
at 20 °C was retrieved from the Bragg peak recorded at q=1.5 Å−1
(Fig. 6C), and is virtually the same as for pure DPPC bilayers (Table 2).
This also holds true for the area per lipid, but only under the
assumption of conserved chain tilt. In the ﬂuid phase the bilayer
swelling and increase of membrane ﬂuctuation parameter are less
pronounced (Δ(d−dHH)=+5 Å and Δσ=+4 Å; Table 2).
Finally, the inﬂuence of valsartan in the ﬂuid phase at 50 °C was
explored in a concentration range from x=0 to 0.20. The key results
from the SAXS experiments are given in the panels A–E of Fig. 7 and
are complemented by the measured effective molecular volume V of
Fig. 5. Temperature scan experiment with DPPC/valsartan from 20 to 50 °C. The concentration of valsartan was 5 mol% and the scan rate was 1 °C/min. Structural changes during the
main transition are observed simultaneously in the SAXS (A) andWAXS (B) regime. The contour plots demonstrate that the lamellar repeat distance decrease is accompanied by the
loss of the chain order. In panel (C) the intensity drop of theWAXS peak at q~1.5 Å−1 is shown, and as seen panel (D) the area/chain constantly increases already in the gel phase. For
comparison, the DSC data have been included in the graphs C and D by vertical lines: transition temperatures are identiﬁed with dashed-dotted lines and the complete transition-
regime is marked by dotted lines (cp. Fig. 2).
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valsartan measurement, all other structural results follow monoto-
nous trends as a function of the valsartan concentration. The induced
membrane thinning from 38.3 to 34.8 Å (ΔdHH~3.5 Å; Fig. 7B) is
accompanied by a steady increase in the mean ﬂuctuation of the
bilayers (Fig. 7C). Accordingly, the water spacing, d−dHH (Fig. 7D)Table 2
Structural data on pure DPPC bilayers and DPPC with 20 mol% valsartan.
DPPC
(20 °C)
DPPC
(50 °C)
DPPC/valsartan
(20 °C)
DPPC/valsartan
(50 °C)
d (Å) 63.5a 67.0a 86.3 68.8
dHH (Å) 44.2a 38.3a 41 35
d − dHH (Å) 19.3a 28.7a 46 34
A (AC) (Å2) 47.9 (20.3)a 64a 48d (20.4)/– 64/58e
σ (Å) 1–2b 6c 14b 10
a Structural data taken from the review [42].
b Estimated values from global data analysis applying the paracrystalline theory.
c Data concerning the root mean square ﬂuctuation in pure DPPC rely on data from
[35,88].
d The partial area per lipid in the gel phase was calculated under the assumption of a
chain conserved chain tilt.
e The partial areas ADPPC and Avalsartan were obtained by applying Eq. (3). Data refer to
X-ray experiments of Fig. 6.increases continuously. Also the effective area per molecule, A,
displays an almost linear behavior, if the 2 mol% valsartan measure-
ment is neglected. This suggests that valsartan does not affect the
lateral area of DPPC signiﬁcantly and allows us to estimate the partial
molecular areas for DPPC and valsartan applying Eq. (3) (solid line in
Fig. 7E). ADPPC results in 64 Å2±1 Å2 and Avalsartan=58±1 Å2. ADPPC is
well in agreement with literature data [42]. In Fig. 7F the behavior of
the effective molecular volume of the studied DPPC/valsartan
mixtures as a function of drug content is shown. A linear decrease
of V is observed, similar to the previously reported volume reduction
investigated for different sterol/PC mixtures [44]. However, unlike
sterols, there is no condensation effect of valsartan on DPPC, because
theweighted average of the baremolecular volumes ﬁts themeasured
data fairly well (Eq. (6)). This agreeswell with our observations on the
lateral areas.
4. Discussion
4.1. Lipid conformational changes
Multilamellar vesicles of DPPC in excess of water undergo an
endothermic melting transition, in which the hydrocarbon chains
change from an all-trans conformation (gel phase) to a trans-gauche
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Fig. 6. X-ray scattering curves of DPPC/valsartan multilamellar vesicles at 20 °C and 50 °C (A), and their corresponding electron density proﬁles (B). In panel C theWAXS peak arising
from the hexagonal chain packing is plotted. The full red lines in panels A and C give the best ﬁt to the data. The most signiﬁcant structural parameters are summarized in Table 2.
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rotational mobility of both the lipid chains and the polar head group
[30,35,63]. From dilatomeric and calorimetric experiments it is known
that the main contributions to the excess of speciﬁc heat during this
transition are due to volume expansion and trans-gauche isomeriza-
tions of the hydrocarbon chains. For DPPC bilayers, the van der Waals
interaction energy accounts for 63% of the total enthalpy and changes
in rotamer energy amount to 32% [64]. The number of induced gauche
rotamers per DPPC molecule in the ﬂuid phase has been estimated to
be 5.6 [65]. The lipid conformation in the ripple phase is not fully
understood yet. Several structural and dynamical studies [66–71] are
consistent with the view that the ripple formation is related to the
coexistence of alternating ﬂuid- and gel-like domains [72], but
alternative models describing the Pß′ phase built up by a single gel
phase have also been put forward [73].
The incorporation of valsartan into the DPPC bilayers is expected to
change at least in part the molecular packing and with it the
conformational state of the lipids. The ﬁrst indication for this notion is
given by the DSC results (Fig. 2) demonstrating that already at 1 mol%,
the pretransition is almost completely suppressed, a hint for its polar
interface activity. Increasing the concentration of valsartan causes a
lowering of Tm and a concomitant increase in ΔT (Table 1). This
behavior is commonly found for many other membrane additives.Most prominent examples are given for PC-sterol interactions, in
which the sterol incorporation renders on one hand the gel phase less
solid, but on the other hand the Lα phase less ﬂuid [74,75], and as a
consequence reduces the cooperativity of the main transition
(increase in ΔT). Direct evidence for this hypothesis is given by the
Raman data in Fig. 3. Here, the C-C stretching mode ratios of the
gauche to trans conformations are analyzed. The intensity ratio of
these two bands (I1090/I1130) is sensitive to changes in the conforma-
tional acyl chain order [56]. Fig. 3A displays the transition of pure
DPPC bilayers, which reproduces well the thermal events (cp. Fig. 2),
and is in agreement with other published Raman data on DPPC
bilayers [54,76]. Clearly, the situation is altered in the presence of
20 mol% of valsartan. The overall intensity ratio difference ΔI drops
(Fig. 3B), and as shown in Fig. 3C, this is caused by a slight disturbance
of the chain order in the gel phase, but is to the greatest part due to a
reduction of the chain disorder in the ﬂuid phase. Similar interaction
behavior with DPPC bilayers have been reported recently for the novel
synthetic pyrrolidinone analog MMK3 [23] as well as for losartan [76].
4.2. Altered lipid packing
Lipid chain conformation and lipid chain packing within the
bilayer are strictly related, but are manifested in different
FA
B E
D
C
30
35
0.00 0.05 0.10 0.15 0.20
4
5
6
7
8
9
10
11
12
13
 valsartan concentration
0.00 0.05 0.10 0.15 0.20
 valsartan concentration
σ 
(Å
)
66.5
67.0
67.5
68.0
68.5
69.0
d 
(Å
)
34
35
36
37
38
39
d H
H (Å
)
d-
d H
H (Å
)
1080
1100
1120
1140
1160
1180
1200
1220
1240
1260
V 
(Å3
)
61
62
63
64
65
66
67
68
69
A 
(Å
2
)
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ﬁndings are discussed. First, the total enthalpy of the main transition
increases with the concentration of valsartan, i.e., from 7.4 to 9.8 kcal/
mol (Table 1). Including also the enthalpic contributions of the
pretransition this trend is slightly reversed for lower valsartan
concentrations. Note that, for x=0, 0.01 and 0.05, ΔHpre+ΔHm
amounts to 8.5, 7.9 and 7.7 kcal/mol, respectively, but the overall
enthalpy of 9.8 kcal/mol is clearly the greatest at 20 mol% valsartan
content. Such an enthalpy increase of themain transition, especially at
high drug concentrations, was also reported for DPPC-losartan
interactions, where ΔHm=9.1 kcal/mol for x=0.2 [22]. The same
behavior was found for dimyristoyl-PC-losartan interactions: an
overall slight enthalpy decrease for drug concentrations from x=0
to 0.10 follows a monotonous enthalpy increase from x=0.1 to 0.5
[77]. This enthalpy trend at higher drug concentrations is somewhat
unexpected, recalling that the change in the rotamer energy is
reduced in the presence of valsartan, or in other words, less trans-
gauche isomerizations of the hydrocarbon chains are expected during
the turnover from the gel to the ﬂuid state, which in principle means a
reduction of the transition enthalpy. Consequently this means that
valsartan most probably increases the van der Waals interaction
contribution (other energetic contributions to the main transition
such as hydrogen bonds account for less than 5% [64]). A possible
explanation would be that above a certain critical drug concentration,
valsartan not only constitutes a membrane impurity, but instead
mediates chain interdigitation in the gel phase. For instance it was
shown that for distearoyl-PC (in the presence of ethanol) the enthalpy
of the interdigitated LβI to Lα phase transition is about 1 kcal/mol
bigger as compared to the main transition of pure distearoyl-PC [78].
Second, this hypothesis would also deliver a possible explanation for
the observation of the two component transition for x≥0.05 (cp.
Fig. 2, Table 1). At this point it is speculative to assume that valsartan-rich domains inducing the interdigitated LβI phase coexist with
valsartan-poor regions conserving mainly the Lβ′ phase (Fig. 8A and
B), but as will be outlined in the next two paragraphs, also the Raman
and X-ray experiments are in line with this interpretation.
Levin and co-workers demonstrated that the intensity ratio I2850/
I2880 of the symmetric and asymmetric C–H stretching bands can be
considered not only a general order parameter to monitor chain
melting transitions, but also to sense different types of chain
interdigitation [57,79]. For instance, perdeuterated glycerol induces
chain interdigitation in DPPC bilayers, which is reﬂected in a decrease
of the I2850/I2880 ratio [57]. The effects of 20 mol% valsartan on DPPC
bilayers are alike (Fig. 4). The transition temperatures from
calorimetric measurements (Table 1) superimposed to the Raman
data are in reasonable agreement, and furthermore the I2850/I2880 ratio
is slightly decreased in the temperature interval from 20 to 35 °C
(Fig. 4C). Interestingly, the ratios are virtually the same from 36 to
40 °C. In agreement with Levin [57] the I2935/I2880 is not sensitive to
chain interdigitation (see inset Fig. 4C). Thus, two thermal regimes
can be discerned in the gel phase, and following the train of thought of
Levin, the interdigitated domains in the gel phase convert ﬁrst
(Fig. 4C). In the aforementioned depiction, the transition component I
(Tm (I)=34.9 °C; Table 1) would hence be due to the chain melting of
valsartan-rich domains in the LβI phase followed by the transition
component II reﬂecting the chain melting of valsartan-poor domains,
which remained predominately in the Lβ' phase (Table 1). Brieﬂy, a
(LβI+Lβ′)→(Lα+Lβ')→Lα transition sequence is proposed.
This interpretation is also in agreement with X-ray data (Fig. 8). In
the scattering pattern at 20 °C (Fig. 6A and C) two particularities
should be noted. First, the shape of the diffraction peak in the wide
angle range is perfectly symmetric, which implies a hexagonal chain
packing, rather than a chain packing on an orthogonal lattice as found
for pure DPPC bilayers [80,81]. Second, the simple bilayer model
dHH
d
A B
C D
Fig. 8. Schematic illustration of DPPC bilayer structure alterations induced by valsartan. Without drug the Lβ′ phase is present at 20 °C (A). The incorporation of 20 mol% valsartan
induces the formation of valsartan-rich domains with chain interdigitation (LβI phase) and valsartan-poor domains which remain in the Lβ′ phase (B). Panel C demonstrates pure
DPPC bilayers in the Lα phase at 50 °C. The same conditions with 20 mol% valsartan are given in panel D. Dimensions in all panels base on the structural data given in Table 2.
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SAXS pattern perfectly. At q~2.5 Å−1 the best ﬁt (solid red line)
displays a ﬁrst minimum of the form factor (see arrow), which is not
seen in the scattering data. This deviation cannot be explained by the
data scatter. Therefore, following the rationale of former studies
[82,83], a combination of two form factor models was applied. One
referring to a conserved bilayer structure (Lβ′ phase as known from
the pure DPPC system) and the other related to a bilayer with fully
interdigitating non tilted chains (LβI phase). The bilayer thicknesses,
dHH, were determined to be about 45 and 32 Å, respectively, which
comes very close to a conserved Lβ′ [42] and a fully interdigitated LβI
phase. The fraction of the LβI phase was a further ﬁt parameter and
turned out to be in the order of 75%, i.e., accordingly 25% of the sample
remains in the Lβ′ phase. This alternative model improved the ﬁtting
quality signiﬁcantly (see dashed red line), however, the results have
to be takenwith due care. The assumed scenario is reasonable, but it is
not the only possible one. For instance also partial interdigitation may
occur, thus, how the lipids actually rearrange in the presence of
valsartan cannot be ascertained, but most probably some amount of
the lipids in the gel phase are interdigitated, because the measured
form factor displays no clear ﬁrst minima at q=2.5 Å−1. This ﬁnally
means that all experimental data are in accordance with the
illustration given in Fig. 8B.
Last, we would like to point out that a small percentage of lipids
with molten chains are likely to coexist with lipids in all-trans
conformation in order to smoothen borders between LβI and Lβ′ phase
domains. Similar ideas have been also proposed for the stable ripple
phase of PCs [67,71,72].
In the ﬂuid phase, the incorporation of 20 mol% of valsartan does
not alter the bilayer structure as drastically. The data are satisfactorily
ﬁtted with the common bilayer model [37] (Figs. 6A and B, upper
curves). Nevertheless, there is a pronounced thinning of themembrane thickness, dHH, from 38.3 to 35 Å (Fig. 7B, Table 2),
which might be explained by induced partial interdigitation (illus-
trated in Figs. 8C and D). In fact the partial lateral areas of valsartan are
comparable to those of DPPC. Hence valsartan may partition into the
membrane such that it basically replaces one DPPC molecule and
shields the methyl terminus of the DPPC hydrocarbons in the
opposing membrane leaﬂet. This further supports the hypothesis
that the enthalpy increase of the main transition at high valsartan
concentrations is mainly caused by an increase of the van der Waals
energy contribution.
4.3. Bilayer swelling and stacking disorder
The equilibriumwater layer thickness between adjacent bilayers is
determined by the inter-membrane forces. For neutral (non-charged)
membranes the attractive van der Waals force is balanced by the
repulsive Helfrich undulation force. Other short range forces such as
steric repulsion or hydration forces do not play any role in our study,
because the inter-membrane distances are far too big (for a review see
[84]). As can be seen in Figs. 8A and 8C (Table 2) the water layer
thickness is usually bigger in the Lα than in the Lβ′ phase. This is
readily understood, because the bending rigidity of a ﬂuid bilayer is
smaller, which in turn causes an increased Helfrich repulsion force
[34]. However, this is not the case for the DPPC/valsartan system. The
opposite holds true, the water layer thickness is bigger in the gel
phase as compared to the ﬂuid phase (Figs. 8B and D; Table 2). Even
more, the amount of correlated bilayers in the gel phase is smaller
than in the Lα phase, which is visible to the naked eye in Fig. 6A: the
ﬁrst order Bragg-peak intensity is rather minute, tantamount to the
fact that the pattern is mainly displaying diffuse form factor scattering
arising from spatially uncorrelated bilayers. However, in the presence
of valsartan also electrostatic repulsion between the membranes has
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[86], which means that under the given experimental conditions (pH
5–6), most of the valsartan molecules are deprotonized at their
tetrazole ring, i.e., they carry a negative charge (Fig. 1). This causes a
negative charge density at the bilayer surfaces, and hence an
additional repulsion between adjacent bilayers. The observed swell-
ing of the lamellar stacking in the MLVs in the presence of valsartan is
therefore governed by electrostatic forces. Note also, that the area per
lipid, A, and the surface charge density are indirectly proportional,
which means that the electrostatic repulsion decreases above Tm.
Since the area per molecule increases by about 30% (Table 2, Fig. 7E),
also the electrostatic force, fe, should decrease, if the valsartan
concentration in the bilayers remains the same. In other words, the
swelling of the bilayers in the ﬂuid phase is less pronounced, because
the electrostatic repulsion is weaker. Please note that other effects like
an altered valsartan partitioning in the ﬂuid bilayers and/or different
penetration depths of valsartan in the ﬂuid bilayer would also alter
the electrostatic force. Nevertheless, the additional electrostatic
repulsion explains the relatively high membrane mean square
ﬂuctuations, σ, in the presence of valsartan (Table 2 and Fig. 7C). It
is well known that positional membrane correlations are a function of
the bilayer bending rigidity constant KC, but also depend on the bulk
compressibility modulus B (cp. Eq. (1)). B is governed by the
interaction potential well and decreases with increasing electrostatic
repulsion [34].
5. Conclusion
As documented in the results/discussion sections valsartan
induces a wide range of alterations in the model membrane system
of DPPC. The most striking changes are: (i) the suppression of the
pretransition at low drug concentrations; (ii) the induction of a two
component main transition at higher drug concentrations; (iii) the
increase of gauche conformers in the lipid chains at ambient
temperature and its relative reduction above Tm; (iv) the pronounced
swelling of the lamellar stacking in the MLVs, especially strongly
expressed in gel phase; and (v) the increase of the membrane
ﬂuctuation parameter in both phases. Notably all these observations
are in accordance with the illustrations given in Fig. 8. Above a certain
drug concentration threshold, in the case of valsartan x≥0.05, in part
chain interdigitation is induced in the gel phase bilayers (LβI phase).
With increasing temperature ﬁrst domains in the LβI phase convert to
the Lα phase, and 1–2 °C thereafter the rest of the gel phase turns over.
Of greater biological relevance, however, are the interactions of
valsartan with the DPPC bilayers in the ﬂuid state. Most importantly,
valsartan is (i) well incorporated in the membrane interface (no
experimental signs for detachment were found, since bilayer swelling
and lattice disorder increase linearly with x), (ii) the common bilayer
proﬁle is conserved, but a clearly thinner membrane core is observed
for high valsartan concentrations, which goes along with (iii) a lateral
expansion of the apparent area per lipid. These are important
structural alterations of the bilayer and the results are conform with
the proposed two-stepmechanism that the ARB's insertion in the lipid
bilayer is followed by the lateral diffusion to the AT1 binding site [13].
However, which role the observed structural membrane modiﬁca-
tions play for valsartan's ﬁnal accessibility to the AT1 receptor remains
unclear. Obviously different lipidic environments could further
modulate the drugs potency. In this respect, the role of cholesterol
and lipid diversity in plasma membranes might be signiﬁcant
[44,74,75,87], and are under investigation in our group.
Acknowlegments
We wish to acknowledge pharmaceutical company Novartis for
the generous donation of bioactive compound valsartan.References
[1] M. Paul, A.P. Mehr, R. Kreutz, Physiology of local renin–angiotensin systems,
Physiol. Rev. 86 (2006) 747–803.
[2] M. De Gasparo, K.J. Catt, T. Inagami, J.W. Wright, Th. Unger, International Union of
Pharmacology. XXIII. The angiotensin II receptors, Pharmacol. Rev. 52 (2000)
415–472.
[3] B. Rubin, M.J. Antonaccio, Z.P. Horovitz, Captopril (SQ 14, 225) (D-3-mercapto-2-
methylpropanoyl-L-proline): a novel orally active inhibitor of angiotensin-
converting enzyme and antihypertensive agent, Progr. Cardiovascular Diseases
21 (1978) 183–194.
[4] C.I. Johnston, Angiotensin receptor antogonists: focus on losartan, Lancet 346
(1995) 1403–1407.
[5] J.L. Pool, M. Azizi, M. Azizi, J.-C. Aldigier, A. Januszewicz, W. Zidek, Y. Chiang,
Aliskiren, an orally effective renin inhibitor, provides sntihypertensive efﬁcacy
alone and in combination with valsartan, J. Am. Hypert. 20 (2007) 11–20.
[6] C. Sakarellos, K. Lintner, F. Piriou, S. Fermandjian, Conformation of the central
sequence of angiotensin II and analogs, Biopolymers 22 (1983) 663–687.
[7] P.C. Wong, T.B. Barnes, A.T. Chiu, D.D. Christ, J.V. Duncia, W.F. Herblin, P.B.M.W.M.
Timmermans, Losartan (DuP 753), an orally active nonpeptide angiotensin II
receptor antagonist, Cardiovasc. Drug Rev. 9 (1991) 317–339.
[8] I. Martin, J.M. Ruysschaert, Common properties of fusion peptides from diverse
systems, Biosci. Rep. 20 (2000) 483–500.
[9] E.L. Schiffrin, Vascular and cardiac beneﬁts of angiotensin receptor blockers, Am. J.
Med. 113 (2002) 409–418.
[10] L.M. Ruilope, E.A. Rosei, G.L. Bakris, G. Mancia, N.R. Poulter, S. Taddei, T. Unger, M.
Volpe, B. Waeber, F. Zannad, Angiotensin receptor blockers: therapeutic targets
and cardiovascular protection, Blood Press. 14 (2005) 196–209.
[11] G. Reboldi, F. Angeli, C. Cavallini, G. Gentile, G. Mancia, P. Verdecchia, Comparison
between angiotensin-converting enzyme inhibitors and angiotensin receptor
blockers on the risk of myocardial infarction, stroke and death: a meta-analysis,
J. Hypertens. 26 (2008) 1282–1289.
[12] T. Mavromoustakos, A. Kolocouris, M. Zervou, P. Roumelioti, J.M. Matsoukas, R.
Weisemann, An effort to understand the molecular basis of hypertension through
the study of conformational analysis of losartan and sarmesin using a combination
of Nuclear Magnetic Resonance spectroscopy and theoretical calculations, J. Med.
Chem. 42 (1999) 1714–1722.
[13] P. Zoumpoulakis, A. Zoga, P. Roumelioti, N. Giatas, S.G. Grdadolnik, E. Iliodromitis,
D. Vlahakos, D. Kremastinos, J.M. Matsoukas, T. Mavromoustakos, Conformational
and biological studies for a pair of novel synthetic AT1 antagonists. Stereoelec-
tronic requirements for antihypertensive efﬁcacy, J. Pharm. Biomed. Anal. 31
(2003) 833–844.
[14] P. Zoumpoulakis, A. Politi, S.G. Grdadolnik, J.M. Matsoukas, T. Mavromoustakos,
Structure elucidation and conformational study of V8. A novel synthetic non
peptide AT1 antagonist, J. Pharm. Biomed. Anal. 40 (2006) 1097–1104.
[15] T. Mavromoustakos, M. Zervou, P. Zoumpoulakis, I. Kyrikou, N.P. Benetis, L.
Polevaya, P. Roumelioti, N. Giatas, A. Zoga, P.M. Minakakis, A. Kolocouris, D.
Vlahakos, S.G. Grdadolnik, J.M. Matsoukas, Conformation and bioactivity. Design
and discovery of novel antihypertensive drugs, Curr. Top. Med. Chem. 4 (2004)
385–401.
[16] T. Mavromoustakos, P. Zoumpoulakis, I. Kyrikou, A. Zoga, E. Siapi, M. Zervou, I.
Daliani, D. Dimitriou, A. Pitsasa, C. Kamoutsis, P. Laggner, Efforts to understand the
molecular basis of hypertension trough drug:membrane interactions, Curr. Top.
Med. Chem. 4 (2004) 445–459.
[17] J.N. Cohn, G. Tognoni, A randomized trial of the angiotensin-receptor blocker
valsartan in chronic heart failure, N. Engl. J. Med. 345 (2001) 1667–1675.
[18] A. Chiolero, M. Burnier, Pharmocology of valsartan, an angiotensin II receptor
antagonist, Expert Opin. Invest. Drugs 7 (1998) 1915–1925.
[19] M. De Gasparo, S. Whitebread, Binding of valsartan to mammalian angiotensin
AT1 receptors, Regul. Pept. 59 (1995) 503–511.
[20] P. Buhlmayer, P. Furret, L. Criscione, M. De Gasparo, S. Whitebread, T. Schildin, R.
Lattmann, J. Wood, Valsartan, a potent orally active angiotensin II antagonist
developed from structurally new aminoacid series, Bioorg. Med. Chem. Lett. 4
(1994) 29–34.
[21] Y. Furukawa, S. Kishimoto, K. Nishikawa, Hypotensive Imidazole-5-Acetic Acid
Derivatives. U.S. Patent 4355040, (1982).
[22] P. Zoumpoulakis, I. Daliani, M. Zervou, I. Kyrikou, E. Siapi, G. Lamprinidis, E.
Mikros, T. Mavromoustakos, Losartan's molecular basis of interaction with
membranes and AT1 receptor, Chem. Phys. Lipids 125 (2003) 13–25.
[23] C. Fotakis, S. Gega, E. Siapi, C. Potamitis, K. Viras, P. Moutevelis-Minakakis, C.G.
Kokotos, S. Durdagi, S. Golic Grdadolnik, B. Sartori, M. Rappolt, T. Mavromoustakos,
Interactions at the bilayer interface and receptor site induced by the novel synthetic
pyrrolidinone analog MMK3, Biochim. Biophys. Acta 1768 (2010) 422–432.
[24] L.G. Herbette, Pharmacokinetic and pharmacodynamic design of lipophilic drugs
based on a structural model for drug-interactions with biological membranes,
Pesticide Sc. 35 (1992) 363–368.
[25] H.S. Young, V. Skita, R.P. Mason, L.G. Herbette, Molecular-basis for the inhibition of
1, 4-dihydropyridine calcium-channel drugs binding to their receptors by a non-
speciﬁc site interaction mechanism, Biophys. J. 61 (1992) 1244–1255.
[26] T. Mavromoustakos, D.P. Yang, A. Makriyannis, Small angle x-ray diffraction and
differential scanning calorimetric studies on O-methyl-(−)-Δ8 tetrahydrocan-
nabinol and its 5′ iodinated derivative in membrane bilayers, Biochim. Biophys.
Acta 1237 (1995) 183–188.
[27] M. McIntyre, S.E. Gaffe, R.A. Michaluck, J.L. Reid, Losartan, an orally active
angiotensin (AT1) receptor antagonist: a review of its efﬁcacy and safety in
essential hypertension, Pharmacol. Ther. 74 (1997) 181–194.
1763C. Potamitis et al. / Biochimica et Biophysica Acta 1808 (2011) 1753–1763[28] F.A. Oliveira, R. Morgado, M.V. Lima, B.A. Mello, A. Hansen, G.G. Batrouni,
Comment on “dynamical foundations of nonextensive statistical mechanics”,
Phys. Rev. Lett. 90 (2003) 218901.
[29] T.J. Netticadan, T.F. Ashavaid, K.G. Nair, Characterisation of the canine cardiac
sarcolemma in experimental mzocardial ischemia, Indian J. Clin. Biochem. 12
(1997) 49–54.
[30] R. Koynova, M. Caffrey, Phases and phase transitions of the phosphatidylcholines,
Biochim. Biophys. Acta 1376 (1998) 91–145.
[31] M.D. Housley, K.K. Stanley, Dynamics of Biological Membranes, John Wiley and
Sons, New York, 1982.
[32] I.W. Levin, R.N. Lewis, Fourier transform Raman spectroscopy of biological
materials, Anal. Chem. 62 (1990) 1101A–1111A.
[33] J.C. Huang, J.R. Lapides, I.W. Levin, Phase-transition behaviour of saturated,
symmetric chain phospholipid bilayers dispersions determined by Raman
spectroscopy: correlation between spectral and thermodynamic parameters,
J. Am. Chem. Soc. 104 (1982) 5926–5930.
[34] M. Rappolt, G. Pabst, Flexibility and structure of ﬂuid bilayer interfaces, in: K. Nag
(Ed.), Structure and dynamics of membranous interfaces, John Wiley & Sons,
Hoboken, 2008, pp. 45–81.
[35] G. Pabst, H. Amenitsch, D.P. Kharakoz, P. Laggner, M. Rappolt, Structure and
ﬂuctuations of phosphatidylcholines in the vicinity of the main phase transition,
Phys. Rev. E 70 (2004)8 021908-1-021908-9.
[36] H. Amenitsch, M. Rappolt, M. Kriechbaum, H. Mio, P. Laggner, S. Bernstorff, First
performance assessment of the small-angle X-ray scattering beamline at
ELETTRA, J. Synchrotron Rad. 5 (1998) 506–508.
[37] G. Pabst, M. Rappolt, H. Amenitsch, P. Laggner, Structural information from
multilamellar liposomes at full hydration: full q-range ﬁtting with high quality x-
ray data, Phys. Rev. E 62 (2000) 4000–4009.
[38] G. Pabst, J. Katsaras, V.A. Raghunathan, M. Rappolt, Structure and interactions in the
anomalous swelling regime of phospholipid bilayers, Langmuir 19 (2003) 1716–1722.
[39] G. Pabst, Global properties of biomimetic membranes: perspectives on molecular
features, Biophys. Rev. Lett. 1 (2006) 57–84.
[40] M. Rappolt, Bilayer thickness estimations with “poor” diffraction data, J. Appl.
Phys. 107 (2010)8 art. no. 084701.
[41] J.F. Nagle, S. Tristram-Nagle, Structure and interactions of lipid bilayer: role of
ﬂuctuations, in: J. Katsaras, T. Gutberlet (Eds.), Lipid bilayers. Structure and
interactions, Springer, Berlin, 2000, pp. 1–23.
[42] J.F. Nagle, S. Tristram-Nagle, Structure of lipid bilayers, Biochim. Biophys. Acta
1469 (2000) 159–195.
[43] S.W. Chiu, E. Jakobsson, R.J. Mashl, H.L. Scott, Cholesterol-inducedmodiﬁcations in
lipid bilayers: a simulation study, Biophys. J. 83 (2002) 1842–1853.
[44] A. Hodzic, M. Rappolt, H. Amenitsch, G. Pabst, Differential modulation of
membrane structure and ﬂuctuations by plant sterols and cholesterol, Biophys.
J. 94 (2008) 3935–3944.
[45] A.I. Greenwood, S. Tristram-Nagle, J.F. Nagle, Partial molecular volumes of lipids
and cholesterol, Chem. Phys. Lipids 143 (2006) 1–10.
[46] E. Marti, H.R. Oswald, P. Bühlmyer, W. Marterer, Valsartan salts, European Patent
Bulletin EP1313714B1 (2008).
[47] N. Albon, J.M. Sturtevant, Nature of the gel to liquid crystal transition of synthetic
phosphatidylcholines, Proc. Natl. Acad. Sci. USA 75 (1978) 2258–2260.
[48] S. Tristram-Nagle, R. Zhang, R.M. Suter, C.R. Worthington, W.J. Sun, J.F. Nagle,
Measurement of chain tilt angle in fully hydrated bilayers of gel phase lecithins,
Biophys. J. 64 (1993) 1097–1109.
[49] J. Katsaras, S. Tristram-Nagle, Y. Liu, R.L. Headrick, E. Fontes, P.C. Mason, J.F. Nagle,
Clariﬁcation of the ripple phase of lecithin bilayers using fully hydrated, aligned
samples, Phys. Rev. E 61 (2000) 5668–5677.
[50] R.C. Spiker, I.W. Levin, Raman spectra and vibrational assignments for dipalmitoyl
phosphatidylcholine and structurally related molecules, Biochim. Biophys. Acta
388 (1975) 361–373.
[51] N. Yellin, I.W. Levin, Hydrocarbon chain disorder in lipid bilayers: temperature
dependent Raman spectra of 1, 2-diacyl phosphatidylcholine-water gels, Biochim.
Biophys. Acta 489 (1977) 177–190.
[52] N. Yellin, I.W. Levin, Hydrocarbon chain trans-gauche isomerization in phospho-
lipid bilayer gel assemblies, Biochemistry 16 (1977) 642–647.
[53] C.B. Fox, R.H. Uibel, J.M. Harris, Detecting phase transitions in phosphatidylcholine
vesicles by Raman microscopy and self-modeling curve resolution, J. Phys. Chem.
B 111 (2007) 11428–11436.
[54] T.J. O'Leary, P.D. Ross, I.W. Levin, Effects of anesthetic and nonanesthetic steroids
on dipalmitoylphosphatidylcholine liposomes: a calorimetric and Raman spec-
troscopic investigation, Biochemistry 23 (1984) 4636–4641.
[55] N.B. Colthulp, L.H. Daly, S.E. Wiberley, Introduction to Infrared and Raman
Spectroscopy, Academic Press, 1990.
[56] R.K. Bista, R.F. Bruch, A.M. Covington, Variable-temperature Raman spectro-
microscopy for a comprehensive analysis of the conformational order in
PEGylated lipids, J. RamanSpectrosc. 40 (2008) 463–471.
[57] T.J. O'Leary, I.W. Levin, Raman spectrosopic study of an interdigitated lipid bilayer
diplamitoylphosphatidylcholine dispersed in glycerol, Biochim. Biophys. Acta 776
(1984) 185–189.
[58] J.R. Silvius, M. Lyons, P.L. Yeagle, T.J. O'Leary, Thermotropic properties of bilyers
containing blanched-chain phospholipids, calorimetric, Raman and 31P NMR
studies, Biochemistry 24 (1985) 5388–5395.[59] M. Rappolt, G. Rapp, Structure of the stable and metastable ripple phase of
dipalmitoylphosphatidylcholine, Eur. Biophys. J. 24 (1996) 381–386.
[60] R. Hosemann, S.N. Bagchi, Direct Analysis of Diffraction by Matter, North-Holland
Publ. Co., Amsterdam, 1962.
[61] A. Caillé, Remarques sur la diffusion des rayons X dans les smectiques A, C. R. Acad.
Sc. Paris B 274 (1972) 891–893.
[62] R. Zhang, S. Tristram-Nagle, W. Sun, R.L. Headrick, T.C. Irving, R.M. Suter, J.F. Nagle,
Small-angle x-ray scattering from lipid bilayers is well described by modiﬁed
Caillé theory but not by paracrystalline theory, Biophys. J. 70 (1996) 349–357.
[63] A. Seelig, J. Seelig, The dynamic structure of fatty acyl chains in a phospholipid
bilayer measured by deuterium magnetic resonance, Biochemistry 13 (1974)
4839–4845.
[64] J.F. Nagle, D.A. Wilkinson, Lecithin bilayers. Density measurements and molecular
interactions, Biophys. J. 23 (1978) 159–175.
[65] D.A. Wilkinson, J.F. Nagle, Dilatometry and calorimetry of saturated phosphati-
dylethanolamine dispersions, Biochemistry 20 (1981) 187–192.
[66] W.J. Sun, S. Tristram-Nagle, R.M. Suter, J.F. Nagle, Structure of the ripple phase in
lecithin bilayers, Proc. Natl. Acad. Sci. USA 93 (1996) 7008–7012.
[67] M. Rappolt, G. Pabst, G. Rapp, M. Kriechbaum, H. Amenitsch, C. Krenn, S.
Bernstorff, P. Laggner, New evidence for gel-liquid crystalline phase coexistence
in the ripple phase of phosphatidylcholines, Eur. Biophys. J. 29 (2000) 125–133.
[68] R.J. Wittebort, C.F. Schmidt, R.G. Grifﬁn, Solid-state carbon-13 nuclear magnetic
resonance of the lecithin gel to liquid-crystalline phase transition, Biochemistry
20 (1981) 4223–4228.
[69] K. Pressl, K. Jørgensen, P. Laggner, Characterization of the sub-main-transition in
distearoylphosphatidylcholine studied by simultaneous small- and wide-angle X-
ray diffraction, Biochim. Biophys. Acta 1325 (1997) 1–7.
[70] K. Jørgensen, Calorimetric detection of a sub-main transition in long-chain
phosphatidylcholine lipid bilayers, Biochim. Biophys. Acta 1240 (1995)
111–114.
[71] K.A. Riske, R.P. Barroso, C.C. Vequi-Suplicy, R. Germano, V.B. Henriques, M.T. Lamy,
Lipid bilayer pre-transition as the beginning of the melting process, Biochim.
Biophys. Acta 1788 (2009) 954–963.
[72] T. Heimburg, Amodel for the lipid pretransition: coupling of ripple formationwith
the chain-melting transition, Biophys. J. 78 (2000) 1154–1165.
[73] K. Sengupta, V.A. Raghunathan, J. Katsaras, Novel structural features of the ripple
phase of phospholipids, Europhys. Lett. 49 (2000) 722–728.
[74] T.P. McMullen, R.N. McElhaney, New aspects of the interaction of cholesterol with
dipalmitoylphosphatidylcholine bilayers as revealed by high-sensitivity differen-
tial scanning calorimetry, Biochim. Biophys. Acta 1234 (1995) 90–98.
[75] M.R. Vist, J.H. Davis, Phase equilibria of cholesterol/dipalmitoylphosphatidylcho-
line mixtures: 2 H nuclear magnetic resonance and differential scanning
calorimetry, Biochemistry 29 (1990) 451–464.
[76] C. Fotakis, D. Christodouleas, P. Chatzigeorgiou, M. Zervou, N.-P. Benetis, K. Viras,
T. Mavromoustakos, Development of a CP 31P NMR broadline simulation
methodology for studying the interactions of antihypertensive AT1 antagonist
losartan with phospholipid bilayers, Biophys. J. 96 (2009) 2227–2236.
[77] E. Theodoropoulou, D. Marsh, Interactions of angiotensin II non-peptide AT1
antagonist losartan with phospholipid membranes studied by combined use of
di¡erential scanning calorimetry and electron spin resonance spectroscopy,
Biochim. Biophys. Acta 1461 (1999) 135–146.
[78] E.S. Rowe, T.A. Cutrera, Differential scanning calorimetric studies of ethanol
interactions with distearoylphosphatidylcholine: transition to the interdigitated
phase, Biochemistry 29 (1990) 10398–10404.
[79] I.W. Levin, T.E. Thompson, Y. Barenholz, C. Huang, Two types of hydrocarbon chain
interdigitation in sphingomyelin bilayers, Biochemistry 24 (1985) 6282–6286.
[80] G.S. Smith, E.B. Sirota, C.R. Saﬁnya, N.A. Clark, Structure of the L beta phases in a
hydrated phosphatidylcholine multimembrane, Phys. Rev. Lett. 60 (1988)
813–816.
[81] W.J. Sun, R.M. Suter, M.A. Knewtson, C.R. Worthington, S. Tristram-Nagle, R.
Zhang, J.F. Nagle, Order and disorder in fully hydrated unoriented bilayers of gel
phase dipalmitoylphosphatidylcholine, Phys. Rev. E 49 (1994) 4665–4676.
[82] E. Sevcsik, G. Pabst, A. Jilek, K. Lohner, How lipids inﬂuence the mode of action of
membrane-active peptides, Biochim. Biophys. Acta 1768 (2007) 2586–2595.
[83] S. Danner, G. Pabst, K. Lohner, A. Hickel, Structure and thermotropic behavior of
the Staphylococcus aureus lipid lysyl-dipalmitoylphosphatidylglycerol, Biophys. J.
94 (2008) 2150–2159.
[84] V.A. Parsegian, R.P. Rand, Interaction in membrane assemblies, in: R. Lipowsky, E.
Sackmann (Eds.), Structure and Dynamics of Membranes, North-Holland,
Amsterdam, 1995, pp. 643–690.
[85] G. Cevc, Membrane electrostatics, Biochim. Biophys. Acta 1031 (1990) 311–382.
[86] E. Cagigal, L. Gonzalez, R.M. Alonso, R.M. Jimenez, pKa determinination of
angiotensin II receptor antagonists (ARA II) by spectroﬂuorimetry, J. Pharm.
Biomed. Anal. 26 (2001) 477–486.
[87] M. Rappolt, M.F. Vidal, M. Kriechbaum, M. Steinhart, H. Amenitsch, S. Bernstorff, P.
Laggner, Structural, dynamic and mechanical properties of POPC at low
cholesterol concentration studied in pressure/temperature space, Eur. Biophys.
J. 31 (2003) 575–585.
[88] H.I. Petrache, N. Gouliaev, S. Tristram-Nagle, R.T. Zhang, R.M. Suter, J.F. Nagle,
Interbilayer interactions from high-resolution x-ray scattering, Phys. Rev. E 57
(1998) 7014–7024.
